it has gained 7% since august 1 and medtronic chairman and ceo jeffrey martha is here.ing the trend. what's interesting here is that your diabetes segment is quite small compared to the rest of your business and yet it had an outsized gain during quarter of 12%. what's selling so well and why? >> well, liz, first of all it's great to be here with you today. especially on a good earnings day. liz: helps. >> it does help, right? we beat on the top and bottom line and raised guidance for the year and the beat was broad based across our different businesses including the diabetes business, which you highlighted which over 12% growth, and the reason we're not getting caught up in the glp-1 drama here is we're treating type 1 insulin type 1 patients who really have a pancreas that just isn't quite working quite right and needs our technology and it is not impacted by a glp-1 so this is more of a genetic issue and our technology, what it does is basically mimic a pancreas and with the advancement of technology whether it be continuous glucose monitoring and these algorithms th